In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...
DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...
From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 ...
Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...
A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...
Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...
MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...
Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer ...
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
24/7 Wall St. on MSN6m
Billionaire Healthcare Investor Alex Denner’s Hedge Fund Has 75% of Its Assets in These 3 StocksIf you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell.
The following is a summary of “Hematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study,” published in the March 2025 issue of Journal of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback